| Literature DB >> 35137176 |
Charlotte J Heaven1,2, Hannah C Wanstall2,3, Nicholas T Henthorn1,2, John-William Warmenhoven1,2, Samuel P Ingram1,4, Amy L Chadwick1, Elham Santina1, Jamie Honeychurch1, Christine K Schmidt1, Karen J Kirkby1,2, Norman F Kirkby1,2, Neil G Burnet2, Michael J Merchant1,2.
Abstract
Micronucleus (MN) formation is routinely used as a biodosimeter for radiation exposures and has historically been used as a measure of DNA damage in cells. Strongly correlating with dose, MN are also suggested to indicate radiation quality, differentiating between particle and photon irradiation. The "gold standard" for measuring MN formation is Fenech's cytokinesis-block micronucleus (CBMN) cytome assay, which uses the cytokinesis blocking agent cytochalasin-B. Here, we present a comprehensive analysis of the literature investigating MN induction trends in vitro, collating 193 publications, with 2476 data points. Data were collected from original studies that used the CBMN assay to quantify MN in response to ionizing radiation in vitro. Overall, the meta-analysis showed that individual studies mostly have a linear increase of MN with dose [85% of MN per cell (MNPC) datasets and 89% of percentage containing MN (PCMN) datasets had an R2 greater than 0.90]. However, there is high variation between studies, resulting in a low R2 when data are combined (0.47 for MNPC datasets and 0.60 for PCMN datasets). Particle type, species, cell type, and cytochalasin-B concentration were suggested to influence MN frequency. However, variation in the data meant that the effects could not be strongly correlated with the experimental parameters investigated. There is less variation between studies when comparing the PCMN rather than the number of MNPC. Deviation from CBMN protocol specified timings did not have a large effect on MN induction. However, further analysis showed less variation between studies following Fenech's protocol closely, which provided more reliable results. By limiting the cell type and species as well as only selecting studies following the Fenech protocol, R2 was increased to 0.64 for both measures. We therefore determine that due to variation between studies, MN are currently a poor predictor of radiation-induced DNA damage and make recommendations for futures studies assessing MN to improve consistency between datasets.Entities:
Keywords: DNA damage; cytochalasin-B; micronuclei; radiotherapy
Mesh:
Year: 2022 PMID: 35137176 PMCID: PMC8976228 DOI: 10.1093/mutage/geac001
Source DB: PubMed Journal: Mutagenesis ISSN: 0267-8357 Impact factor: 3.000
Figure 1.PRISMA flow showing how the studies included in the analysis were selected and reasons for the exclusion of other studies. Some studies passed initial phases of the screening due to lack of detail in the title/abstract, however these were later excluded following full-text review. For this reason, some exclusion criteria included are listed twice.
Figure 2.Characteristics of studies included in this meta-analysis. (A) The number of studies using the CBMN assay since its conception in 1985. (B) Cyt-B concentration used (some studies used more than one concentration). (C) Frequency of radiation type used in different studies. (D) Time between irradiation and cyt-B addition. (E) Time between cyt-B addition and MN fixation. (F) Overall time between irradiation and fixation. Red arrows indicate the timings detailed by the Fenech protocol (44, 24–28, and 68–82 h for D, E, and F, respectively).
Figure 3.Effect of dose on MN. R2 of linear regression between (A) MNPC and (B) PCMN and dose split by radiation type. Papers with fewer than three data points were excluded as a linear regression could not be performed. Some papers contained more than one dataset; in this case separate regressions were analyzed. (C) Combined data for MNPC as a function of dose with a linear regression line for dose (R2 = 0.474). (D) Combined data for PCMN as a function of dose (R2 = 0.602). The R2 for the whole datasets (C or D) is shown in a dotted line on graphs A and B.
Figure 4.Effect of physical factors on MN produced per dose. (A) MNPC per dose and (B) PCMN per dose split by particle type. The number of studies presenting results for each particle type is shown in brackets. Linear regressions were performed where there were three or more papers and are shown with trend lines and R2 values on the figure. (C) MNPC and (D) PCMN per dose split by LET.
Figure 5.Effect of species and cell type on MN produced per dose. (A) MNPC split by species. (B–D) MNPC split by cell type where there are more than three papers. Cell types with (B) R2 > 0.75, (C) R2 between 0.5 and 0.75, and (D) R2 < 0.5. (E) PCMN split by species. (F) PCMN split by cell type where there are three or more papers. For all graphs, the number of studies is shown in brackets in the legend and R2 is calculated from linear regression where there are three or more studies included.
Figure 6.Rate of MN induction for cancer vs normal cells per dose. (A) MNPC and (B) PCMN per dose split by normal or cancer cell type. Mutated cells were separated as cells which had possible cancer mutations but had not been proven to be cancerous. One study averaged the healthy and cancer patient results, this has been separated from the other points and is referred to as “mixed blood.” The number of studies is shown in brackets in the legend and R2 is calculated from linear regression where there are three or more studies included.
Figure 7.Experimental protocol effects on MN produced per dose. (A) MNPC per dose and (B) PCMN per dose split by cyt-B concentration. The number of studies presenting results for each concentration is shown in brackets. Linear regressions were performed where there were three or more studies and are shown with trend lines and R2 values on the figure. (C) MNPC per dose and (D) PCMN per dose split by common protocol timings including the Fenech protocol (orange) [11].
Figure 8.Subpopulation of studies effect of dose and particle type on MN. (A) MNPC and (B) PCMN produced at each dose split by particle type for papers only studying human lymphocytes and following the Fenech protocol timings. The number of studies presenting results for each particle type is shown in brackets. Linear regressions were performed where there were three or more studies and are shown with trend lines and R2 values on the figure.